Crispr Therapeutics AG is trading 12.2% up at $58.45 after CEO Sam Kulkarni delivered an upbeat presentation at the Jefferies Global Healthcare Conference.
- Kulkarni highlighted a strong commercial outlook for CASGEVY and a promising clinical pipeline, driving investor optimism regarding growth prospects.
- The stock's significant move stands out against mixed broader markets, suggesting a specific reaction to the CEO's commentary on clinical progress.